Filovirus Animal Non-clinical Group (FANG) Workshop

 


Workshop Agenda

FANG Workshop

 

DAY 1 – May 20, 2019

Time

Session/Topic

Speakers

7:30-8:30am

Registration (Front Lobby)

8:30-8:40am

Welcome

Bill Dowling, NIAID

8:40-9:05am

FANG Working Group Updates_1

FANG Working Group Updates_2

Bill Dowling, NIAID

Colleen Sico, NIAID

Helen Schiltz, NIAID

Larry Wolfraim, NIAID

Kim Taylor, NIAID

9:05-9:25am

Strain Selection and Seed Stocks

Eric Donaldson, FDA

Kim Taylor, NIAID

Session One: Filovirus Natural History

9:25-9:50am

Overview of Filovirus Disease in Humans: a 2019 update

Ian Crozier, NIAID

9:50-10:10am

Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys: A Critical Study for Development of an EVD Therapeutic under the Animal Rule

Travis Warren, USAMRIID

10:10-10:30am

Rhesus Macaque Model of Ebola virus Disease

Ricardo Carrion, TBRI

10:30-10:45am

Coffee Break

10:45-11:05am

Natural Disease Progression of the Kikwit Ebola Virus Strain in the Rhesus Macaque Animal Model

Richard Bennett, NIAID

11:05-11:25am

Ebolavirus Control Animal Meta-analysis

Nancy Niemuth, Battelle

11:25-12:00pm

Discussion—Q&A

Chairs:

Louise Pitt, USAMRIID

Carol Sabourin, BARDA

12:00 -1:00pm

Lunch

1:00-1:20pm

Natural History of IM Marburg Infection in Cynomolgus Macaques

Sandra Bixler, USAMRIID

1:20-1:40pm

Characterization of Disease in Cynomolgus Macaques Exposed via aerosol with MARV

Kendra Alfson 1, TBRI

1:40-2:00pm

Characterization of Disease in Cynomolgus Macaques Exposed via intramuscular route with MARV

Kendra Alfson 2a, TBRI

2:00-2:20pm

Sudan virus natural history IM

Yenny Goez-Gazi, TBRI

2:20-2:45pm

Discussion—Q&A

Chairs:

Mike Merchlinsky, BARDA

Robert Fisher, FDA

2:45-3:00pm

Coffee Break

Session Two: Ebola Alternate routes

3:00-3:20pm

EBOV Disease NHP Model Development: Intranasal Routes of Exposure

Sara Johnston, USAMRIID

3:20-3:40pm

Comparison of EBOV-vaccine efficacy in IM- and IN-challenged cynomolgus macaques

Anthony Griffiths, Boston University/NEIDL

3:40-4:00pm

Pathogenesis studies and Therapeutic development using Intranasal Models of Ebolavirus infection in the Domestic Ferret

Robert Cross, UTMB

4:00-4:20pm

Vaccination studies in ferrets against EBOV and SUDV

Glenn Marsh, CSIRO

4:20-4:45pm

Discussion—Q&A

Chairs:

Kim Taylor, NIAID

Jeffrey Froude, DTRA

End of Day 1

 


DAY 2 – May 21, 2019

Time

Session/Topic

Speakers

Session Three: Ebola Aerosol Models

8:30-8:50am

Regulatory Considerations In Characterizing Inhalation Exposure Systems using Infectious Microorganisms

Roy Barnewall, Battelle

8:50-9:10am

Considerations for Aerosol Generation and Sampling in Inhalation Studies with Ebola Virus

Paul Dabisch, NBACC/BNBI

9:10-9:30am

Development of a Large Particle Ebola Virus Aerosol Model in Nonhuman Primates

Kyle Bohannon, NIAID

9:30-9:50am

Filovirus Medical Countermeasures (MCM) Studies with Aerosol Challenge in Nonhuman Primates

Sandra Bixler, USAMRIID

9:50-10:10am

Sequential Sampling of Vaccinated Cynomolgus Macaques Following Aerosol Exposure to Ebola Virus

Sara Johnston, USAMRIID

10:10-10:25am

Coffee break

10:25-10:45am

Simon 2 Stage for efficacy of HPIV3/EboGP, EBOVΔVP30 and a GP-based EBOV vaccine against aerosol and intramuscular EBOV challenge in cynomolgus macaques

Elizabeth Zumbrun, USAMRIID

Eric Lee, USAMRIID

10:45-11:00am

Practical Application of the MCS JVAP-USAMRIID Co-Developed Lung Scoring System

Clint Florence, JVAP

 

11:00-11:20am

Evaluation of Post-exposure ZMapp-N Infusion Against Challenge with Aerosolized Ebola Virus

James Pettitt, Mapp Biopharma

11:20-11:45am

Discussion—Q&A

Chairs:

Callie Bounds, JVAP

Bill Dowling, NIAID

11:45-12:45 pm

Lunch

Session Four: Medical Countermeasures I (MCMs)

12:45-1:05pm

Galidesivir (BCX4430) Broad Spectrum Antiviral Program Update

Ray Taylor, BioCryst

1:05-1:25pm

siRNA-Conjugates for Targeting Hemorrhagic Fever Viruses

Drew Kondratowicz, Genevant Sciences

1:25-1:35pm

Discussion—Q&A

Chair:

Helen Schiltz, NIAID


 

1:35-2:00pm

Quickfire Session (2 minutes each)

  • Christopher Basler, Georgia State University
  • Robert Davey, Boston University
  • Aloysius Klingelhutz, University of Iowa
  • Drishya Kurup, Thomas Jefferson University
  • Axel Lehrer, University of Hawaii at Manoa
  • Nicholas Machesky, Battelle
  • Anita McElroy, University of Pittsburgh
  • David McIlwain, Stanford University
  • Reid Rubsamen, Flow Pharma, Inc.
  • Thomas Rudge, Battelle

2:00-3:00pm

Coffee break and Poster Session

3:00-3:20pm

Development of an antibody cocktail for post-exposure treatment of Sudan virus infection

Andrew Herbert, USAMRIID

3:20-3:40pm

Development of anti-filovirus immunotherapeutics

Zachary Bornholdtv2, Mapp Biopharma

3:40-4:00pm

Development of Sudan Virus Therapeutic Monoclonal Antibodies

John Misasi, NIAID

4:00-4:20pm

Engineering multispecific antibodies as broad filovirus immunotherapeutics

Jonathan Lai, Albert Einstein College of Medicine

4:20-4:40pm

Platforms to respond to emerging viruses powered by human antibody discovery

Robert Carnahan, Vanderbilt University Medical Center

4:40-5:10pm

Discussion—Q&A

Chairs:

Pat Repik, NIAID

Mark Hickman, Medical Countermeasure Systems

End of Day 2

 

DAY 3 – May 22, 2019

Time

Session/Topic

Speakers

Session Five: Updates from the field

8:30-9:00am

DRC update and RCT

Cliff Lane, NIAID

 

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease – in Clinical Trials

9:00-9:20am

Overview and update of mAb114

Wendy Holman/Peter Patriarca, Ridgeback Biotherapeutics

9:20-9:40am

REGN EB3 for the treatment of Ebola Zaire Disease

Alina Baum, Regeneron

9:40-10:00am

ZMapp

Tom Moench, Mapp Biopharma

10:00-10:20am

Broad Spectrum Antiviral Remdesivir for the Treatment of Ebola and Other Emerging Viral Infections

Danielle Porter, Gilead

10:20-10:35am

Discussion—Q&A

Chairs:

Ian Crozier, NIAID

Ronald Reisler, JPEO-CBRND-MCS

10:35-10:50am

Coffee Break

10:50-11:10am

Ebolavirus Research in the Democratic Republic of the Congo

Anne Rimoin, UCLA Fielding School of Public Health

11:10-11:30am

PREVAIL

Lisa Hensley, NIAID

11:30-11:40am

Discussion—Q&A

Chair:

Lisa Hensley, NIAID

11:40-12:30pm

Lunch

Session Six : Medical Countermeasures II (MCMs)

12:30-12:50pm

Quadivalent Filovirus/Lassa Vaccine demonstrates protection against challenge in nonhuman primates

Rong Xu, Profectus Biosciences Inc.

12:50-1:10pm

SUDV and MARV challenge models: What can we learn from the EBOV experience?

Ramon Roozedaal, Janssen

1:10-1:30pm

Advances in Adenovirus-vectored filovirus vaccines

Anna Honko, NIAID

1:30-1:50pm

Recombinant, Live Attenuated Vaccines against Marburg and Sudan Viruses using the VSV Vector Platform

Tom Monath, Crozet BioPharma Consulting

1:50-2:05pm

Discussion—Q&A

Chairs:

Larry Wolfraim, NIAID Daniel Wolfe, BARDA

2:05-2:20pm

Workshop Summary & What’s Next

Chairs:

Louise Pitt, USAMRIID

Ed Nuzum, NIAID

-END OF MEETING-

 


Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top